Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

696 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.
Yuan Z, DeFalco F, Wang L, Hester L, Weaver J, Swerdel JN, Freedman A, Ryan P, Schuemie M, Qiu R, Yee J, Meininger G, Berlin JA, Rosenthal N. Yuan Z, et al. Among authors: rosenthal n. Curr Med Res Opin. 2020 Jul;36(7):1117-1124. doi: 10.1080/03007995.2020.1761312. Epub 2020 May 14. Curr Med Res Opin. 2020. PMID: 32338068
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
Ryan PB, Buse JB, Schuemie MJ, DeFalco F, Yuan Z, Stang PE, Berlin JA, Rosenthal N. Ryan PB, et al. Among authors: rosenthal n. Diabetes Obes Metab. 2018 Nov;20(11):2585-2597. doi: 10.1111/dom.13424. Epub 2018 Jun 25. Diabetes Obes Metab. 2018. PMID: 29938883 Free PMC article.
Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Wang L, Voss EA, Weaver J, Hester L, Yuan Z, DeFalco F, Schuemie MJ, Ryan PB, Sun D, Freedman A, Alba M, Lind J, Meininger G, Berlin JA, Rosenthal N. Wang L, et al. Among authors: rosenthal n. Pharmacoepidemiol Drug Saf. 2019 Dec;28(12):1620-1628. doi: 10.1002/pds.4887. Epub 2019 Aug 27. Pharmacoepidemiol Drug Saf. 2019. PMID: 31456304 Free PMC article.
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N. Udell JA, et al. Among authors: rosenthal n. Circulation. 2018 Apr 3;137(14):1450-1459. doi: 10.1161/CIRCULATIONAHA.117.031227. Epub 2017 Nov 13. Circulation. 2018. PMID: 29133607 Free PMC article.
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V; CREDENCE Study Investigators. Jardine MJ, et al. Among authors: rosenthal n. J Am Soc Nephrol. 2020 May;31(5):1128-1139. doi: 10.1681/ASN.2019111168. J Am Soc Nephrol. 2020. PMID: 32354987 Free PMC article. Clinical Trial.
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
Oshima M, Neuen BL, Jardine MJ, Bakris G, Edwards R, Levin A, Mahaffey KW, Neal B, Pollock C, Rosenthal N, Wada T, Wheeler DC, Perkovic V, Heerspink HJL. Oshima M, et al. Among authors: rosenthal n. Lancet Diabetes Endocrinol. 2020 Nov;8(11):903-914. doi: 10.1016/S2213-8587(20)30300-4. Lancet Diabetes Endocrinol. 2020. PMID: 33065060 Clinical Trial.
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, Cannon CP, Charytan DM, Edwards R, Górriz JL, Jardine MJ, Levin A, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Mahaffey KW, Heerspink HJL. Neuen BL, et al. Among authors: rosenthal n. Eur Heart J. 2021 Dec 21;42(48):4891-4901. doi: 10.1093/eurheartj/ehab497. Eur Heart J. 2021. PMID: 34423370 Clinical Trial.
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V. Mahaffey KW, et al. Among authors: rosenthal n. Circulation. 2019 Aug 27;140(9):739-750. doi: 10.1161/CIRCULATIONAHA.119.042007. Epub 2019 Jul 11. Circulation. 2019. PMID: 31291786 Free PMC article. Clinical Trial.
696 results